Pricing Log in Create free account
Friday 6 November 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue
+11.2%
EPS
+0.58%
Free cash flow
−52.9%
Total debt
+0.31%

Quarter to September 2026, against a year earlier

79.50 4.96 −5.87%
Market cap
$31.5B
P/E
32.6×
Fwd P/E
31.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

DexCom, Inc. 10-Q filed Oct 30, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 5:19 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 1 added · 14 modified; 9 with only figures updated

  1. Modified · Future Developments

    Partnerships: We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. With the introduction of Stelo, we are also pursuing and supporting development partnerships with consumer technology product companies that seek to provide metabolic health insights to their customers.